R&D Systems™ Recombinant Human VEGFR1/Flt-1 (aa 27-328) Fc Chimera, CF

Description

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility.

The Recombinant Human VEGFR1/Flt-1 (aa 27-328) Fc Chimera is derived from NS0. The Recombinant Human VEGFR1/Flt-1 (aa 27-328) Fc Chimera has been validated for the following applications: Bioactivity.

Specifications

• Formulation: Lyophilized from a 0.2μm filtered solution in PBS.
• Gene ID (Entrez): 2321
• Molecular Weight (g/mol): 60.7 kDa (monomer)
• Name: VEGF R1/Flt-1 Fc Chimera, aa 27-328
• Quantity: 50 μg
• Source: Mouse myeloma cell line,NS0-derived human VEGFR1/Flt-1 protein, (N-terminus) Human VEGFR1 (Ser27-lle328) Accession &Num;P17948 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.
• Structural Form: Disulfide-linked homodimer
• Endotoxin Concentration: <0.1 EU per 1μg of the protein by the LAL method.
• Gene Alias: EC 2.7.10, EC 2.7.10.1, FLT, FLT1, FLT-1, Fms-like tyrosine kinase 1, fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor), FRT, Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, vascular endothelial growth factor receptor 1, Vascular permeability factor receptor, VEGF R1, VEGFR1, VEGFR-1
• Conjugate: Unconjugated
• Recombinant: Recombinant
• Purity or Quality Grade: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.